Rapport Therapeutics Quarterly Balance Sheet
NASDAQ: RAPPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Rapport Therapeutics financial position
As of Jun 30, 2026, Rapport Therapeutics reported total assets of $459.0 million, up 60.8% from a year earlier against total liabilities of $36.1 million. Shareholders' equity stood at $422.9 million, or 92.1% of assets. The company held $63.6 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 15.72, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Rapport Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 63.61M | 78.06M | 52.65M | 251.36M | 55.07M | 57.60M | 56.80M | 39.31M | 110.16M | 74.27M | 70.17M | 159.41M |
| Short-Term Investments | 372.46M | 398.73M | 437.89M | 261.67M | 205.38M | 227.78M | 248.47M | 281.35M | 225.97M | — | 77.31M | — |
| Receivables | 293.00K | 58.00K | 0 | — | — | — | — | — | — | — | — | — |
| Total Current Assets | 446.86M | 484.69M | 498.56M | 520.66M | 270.24M | 290.97M | 309.80M | 325.94M | 340.67M | — | 150.87M | — |
| Property, Plant & Equipment | 2.34M | 2.52M | 2.98M | 3.12M | 3.17M | 3.40M | 3.53M | 3.41M | 3.47M | — | 1.92M | — |
| Total Assets | 458.98M | 497.60M | 512.43M | 535.32M | 285.50M | 302.05M | 314.93M | 331.14M | 346.10M | — | 155.42M | — |
| Accounts Payable | 2.80M | 6.56M | 4.19M | 3.23M | 3.18M | 2.14M | 1.95M | 1.32M | 1.88M | — | 2.50M | — |
| Total Current Liabilities | 28.42M | 17.90M | 19.05M | 14.32M | 11.88M | 9.38M | 8.77M | 7.10M | 8.10M | — | 8.80M | — |
| Total Liabilities | 36.06M | 26.09M | 27.78M | 23.71M | 21.98M | 16.22M | 9.51M | 8.03M | 9.21M | — | 14.48M | — |
| Shareholders' Equity | 422.93M | 471.51M | 484.65M | 511.62M | 263.51M | 285.84M | 305.43M | 323.11M | 336.89M | -39.63M | -25.63M | -13.12M |
| Retained Earnings | -311.70M | -255.09M | -235.23M | -201.47M | -174.54M | -147.81M | -123.75M | -103.77M | -86.23M | — | -45.44M | — |
| Net Cash (Debt) | 436.08M | 476.78M | 490.54M | 513.03M | 260.45M | 285.38M | 305.28M | 320.66M | 336.14M | 74.27M | 147.48M | 159.41M |
| Shares Outstanding | 47.96M | 47.81M | 47.77M | 47.65M | 36.50M | 36.50M | 36.58M | 36.58M | 36.58M | — | 4.17M | — |
This table shows 12 quarterly periods of Rapport Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 13 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow RAPP's reporting calendar. What is a balance sheet?